Determination of the substrate-docking site of protein tyrosine kinase C-terminal Src kinase by Lee, Sungsoo et al.
University of Rhode Island
DigitalCommons@URI
Cell and Molecular Biology Faculty Publications Cell and Molecular Biology
2003
Determination of the substrate-docking site of
protein tyrosine kinase C-terminal Src kinase
Sungsoo Lee
University of Rhode Island
Xiaofeng Lin
University of Rhode Island
See next page for additional authors
Follow this and additional works at: https://digitalcommons.uri.edu/cmb_facpubs
Terms of Use
All rights reserved under copyright.
This Article is brought to you for free and open access by the Cell and Molecular Biology at DigitalCommons@URI. It has been accepted for inclusion
in Cell and Molecular Biology Faculty Publications by an authorized administrator of DigitalCommons@URI. For more information, please contact
digitalcommons@etal.uri.edu.
Citation/Publisher Attribution
Lee, S., Lin, X., Nam, N. H., Parang, K., & Sun, G. (2003). Determination of the substrate-docking site of protein tyrosine kinase C-
terminal Src kinase. Proceedings of the National Academy of Sciences, 100(25), 14707-14712. doi: 10.1073/pnas.2534493100
Available at: https://doi.org/10.1073/pnas.2534493100
Authors
Sungsoo Lee, Xiaofeng Lin, Nguyen Hai Nam, Keykavous Parang, and Gongqin Sun
This article is available at DigitalCommons@URI: https://digitalcommons.uri.edu/cmb_facpubs/53
Determination of the substrate-docking site of
protein tyrosine kinase C-terminal Src kinase
Sungsoo Lee*, Xiaofeng Lin*, Nguyen Hai Nam†, Keykavous Parang†, and Gongqin Sun*‡
Departments of *Cell and Molecular Biology and †Biomedical Sciences, University of Rhode Island, Kingston, RI 02881
Edited by R. L. Erikson, Harvard University, Cambridge, MA, and approved October 15, 2003 (received for review July 17, 2003)
Protein tyrosine kinases (PTK) are key enzymes of mammalian
signal transduction. For the fidelity of signal transduction, each
PTK phosphorylates only one or a few proteins on specific Tyr
residues. Substrate specificity is thought to be mediated by PTK–
substrate docking interactions and recognition of the phosphory-
lation site sequence by the kinase active site. However, a substrate-
docking site has not been determined on any PTK. C-terminal Src
kinase (Csk) is a PTK that specifically phosphorylates Src family
kinases on a C-terminal Tyr. In this study, by sequence alignment
and site-specific mutagenesis, we located a substrate-docking site
on Csk. Mutations in the docking site disabled Csk to phosphory-
late, regulate, and complex with Src but only moderately affected
its general kinase activity. A peptide mimicking the docking site
potently inhibited (IC50  21 M) Csk phosphorylation of Src but
only moderately inhibited (IC50  422 M) its general kinase
activity. Determination of the substrate-docking site provides the
structural basis of substrate specificity in Csk and a model for
understanding substrate specificity in other PTKs.
Protein tyrosine kinases (PTK) are a large family of enzymesthat transfer the -phosphate of ATP to Tyr hydroxyl group
in proteins (1). This covalent modification is a fundamental
mechanism in cellular regulation and signal transduction (2).
Activation of specific PTKs is associated with various types of
human cancer and other proliferative diseases, making many
PTKs targets for drug discovery (3, 4). Although all PTKs share
a highly conserved catalytic domain (5), each PTK phosphory-
lates only one or a few protein substrates on specific tyrosine
residues, enabling them to transduce regulatory signals to spe-
cific targets. The tertiary structures of a dozen PTKs have been
determined (5), but the mechanisms by which PTKs recognize
their physiological substrates are still poorly understood.
One of the best understood PTK regulatory systems is the
regulation of Src family PTKs (SFKs) (6). There are nine kinases
in the Src family. They share an overall structural organization,
containing a myristoylation motif, a unique region, an Src
homology (SH)3 domain, an SH2 domain, a catalytic domain,
and a regulatory C-terminal tail. SFKs are regulated by phos-
phorylation on two Tyr residues, one located on the activation
loop (Yact) and the other on the C-terminal tail (Ytail). Yact is the
site of autophosphorylation catalyzed by SFKs through an
intermolecular mechanism, which activates SFKs (7). Ytail is
phosphorylated by another family of PTKs containing two
members, C-terminal Src kinase (Csk) (8) and Csk-homologous
kinase (Chk) (9, 10). Phosphorylated Ytail binds to the SH2
domain intramolecularly (11, 12), which leads to inactivation of
SFKs (13). Additionally, phosphorylation of Yact blocks the
inactivation of SFKs by Ytail phosphorylation (14). Because the
phosphorylation of Yact and Ytail has opposite effects on SFK
function, it is critical that they are specifically phosphorylated by
respective kinase activities. The phosphorylation of Ytail by Csk
and Chk is indeed highly specific and exclusive (15). Only Csk
and Chk phosphorylate the Ytail of SFKs, which are the only
physiological substrates for Csk and Chk. It is not clear whether
Csk and Chk have identical or different specificity among SFKs.
The C-terminal tails of SFKs have a consensus sequence of
TATEXQYtailQXQG, where the X’s are variable residues.
Early efforts to understand Csk substrate specificity used pep-
tides mimicking this phosphorylation site (8, 16). However, such
peptides are 1,000 times less efficient than SFKs as substrates
for Csk (8, 16, 17). By screening a random peptide library, Cole
and coworkers (17) identified an optimal peptide substrate for
Csk with the sequence of EEEIYFFF. The optimal peptide is 500
times better as a substrate than are peptides mimicking the Src
C-terminal tail and bears little resemblance to the physiological
phosphorylation site (17). These studies demonstrate that the
C-terminal tail does not contain sufficient determinants for Csk
recognition. Recent mutagenic studies of Src indicated that,
although the local sequence surrounding the phosphorylation
site played important roles, additional determinants residing
outside the C-terminal tail are required for efficient Ytail phos-
phorylation by Csk (18). These observations suggest that Csk
recognition of Ytail of SFKs involves two types of interactions:
docking interactions between Csk and SFKs and local interac-
tions between the active site of Csk and the tail peptide
sequence. Such bivalent interactions would allow Csk to specif-
ically recognize SFKs and position the Ytail into Csk active site
for phosphorylation. The docking site on Csk and the docking
determinants on SFKs have not been determined.
The tertiary structures of Csk (19, 20) and several SFKs (11,
12, 21) have been determined, but the structures do not provide
clear clues to how Csk recognition of SFKs may be achieved. In
this current study, using structure-guided site-specific mutagen-
esis, we determined a substrate-docking site on Csk that is critical
for its ability to bind to, phosphorylate, and regulate SFKs but
is not important for the general kinase activity. Furthermore, a
peptide mimicking the substrate-docking site potently inhibited
Csk phosphorylation of Src but only moderately inhibited the
general kinase activity of Csk. To our knowledge, this is the first
report of a substrate-docking site on any PTK.
Methods
Chemicals and Reagents. All reagents used for bacterial culture
and protein expression were purchased from Fisher. Chromato-
graphic resins, glutathione-agarose, iminodiacetic acid-agarose,
and Sephadex G25 were purchased from Sigma. DNA primers
were synthesized by Integrated DNA Technologies (Coralville,
IA). [-32P]ATP (6,000 Ci mol1; 1 Ci 37 GBq) was purchased
from Perkin-Elmer. Peptides were synthesized by solid phase
synthesis, purified by HPLC, and confirmed by electrospray mass
spectrometry.
Recombinant Kinase and Substrate Expression and Site-Specific Mu-
tagenesis. Wild type human Csk was expressed in E. coli (DH5)
by using pGEX-Csk-st plasmid (22, 23). Site-specific mutants
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were generated by using QuikChange (Stratagene). The entire
coding regions of the mutant plasmids were sequenced to
confirm that the correct mutations were incorporated. The
GST–Csk fusion proteins were purified by glutathione affinity
chromatography and stored in 50 mM Tris-Cl, pH 8.0, at 20°C
in 30% glycerol. The chicken Src mutant devoid of kinase activity
(kdSrc) was coexpressed with GroEL and GroES chaperone in
BL21(DE3) as described (18). kdSrc was purified by a Ni2-
iminodiacetic acid agarose column as described (24). Lys295Met
mutation abolishes the Src kinase activity but does not affect its
ability to serve as a substrate for Csk (18, 25). Protein concen-
trations were determined by the Bradford method and A280 in the
6 M urea. Purity of the purified enzymes was examined by
SDSPAGE and Coomassie blue staining.
Kinase Activity Assays. Kinase activity of Csk and mutants was
determined by using polyE4Y or kdSrc and [-32P]ATP (600 dpm
pmol1) as the substrates as described (26). Briefly, phosphor-
ylation reactions were performed in 50-l volumes at 30°C in the
protein kinase assay buffer: 50 mM N-(2-hydroxyethyl)pipera-
zine-N-3-propanesulfonic acid (pH 8.0) containing 5% glycerol,
0.005% Triton X-100, and 0.05% 2-mercaptoethanol. The stan-
dard assay used 3 nM WT Csk, 12 mM MgCl2, 0.2 mM ATP, and
1 mg ml1 polyE4Y or 10 M kdSrc. After a 10-min reaction
time, 35 l of the reaction mixture was spotted onto Whatman
filter paper squares (2  1 cm), which were washed in 5%
trichloroacetic acid at 65°C three times for 20 min each. The
radioactivity incorporated into polyE4Y or kdSrc was deter-
mined by liquid scintillation counting. Assays were performed in
duplicate, and each assay was repeated at least twice with
reproducible results.
To determine the catalytic parameters of Csk by using kdSrc
as a substrate, 0.71–7.1 M kdSrc was used as the variable
substrate. The assays were performed as described above. The
reaction minus Csk was used as background controls. The
background was 2,000 cpm, and the signals were in the range
of 10,000–100,000 cpm. No autophosphorylation or phosphor-
ylation of polyE4Y by kdSrc was detected under these conditions.
The Km and kcat values were determined by using double
reciprocal plot.
To determine the inhibition of Csk activity by peptides, Csk
activity in the presence of various concentrations of the peptide
was determined. The kinase activity as a function of the peptide
concentration was fitted into a curve-fitting program (LABFIT) to
determine the IC50.
Csk Inactivation of Src. The ability of Csk and mutants to inactivate
Src was determined as described (14). Appropriate level of Src
activity was incubated with Csk or Csk mutants in the presence
of 0.1 mM ATP and 12 mM MgCl2 at 30°C for 10 min. At the
end of the incubation, 0.4 mgml RCM-lysozyme and
[-32P]ATP was added. Because RCM-lysozyme was preferen-
tially phosphorylated by Src, the residual Src activity after the
initial incubation could be accurately determined without re-
moving Csk from the incubation.
Pull-Down Assay. To determine the interaction between Csk and
kdSrc, pull-down assays were performed. Purified GST, GST-
Csk, or GST-mutant Csk fusion proteins (100 pmol) were
incubated with 200 pmol of kdSrc in 50 l of kinase assay buffer
without ATP and MgCl2 at 30°C for 15 min with gentle agitation.
Glutathione-agarose bead suspension (20 l) was added into
each incubation and incubated for another 15 min. The incuba-
tion mixtures were passed through a small column to collect the
beads, which were then washed three times with 100 l of kinase
assay buffer each. The proteins associated with the beads were
analyzed by SDSPAGE.
Results
Homology Alignment and Ala Scanning Identify a Potential Substrate-
Docking Site in Csk. Csk contains an SH3 and an SH2 domain (27,
28). Previous studies suggest that the SH3 and SH2 domains do
not directly contribute to substrate recognition by Csk (29, 30).
The Csk catalytic domain is composed of an ATP-binding lobe
and a peptide-binding lobe (19, 20). We focused our search for
the substrate-docking site on the peptide-binding lobe, which
contains 180 residues (271–450). Because Csk and Chk are the
only two PTKs capable of phosphorylating SFKs on Ytail, the
docking site must be conserved in Csk and Chk but not in other
PTKs. To locate the structural features uniquely conserved in
Csk and Chk, primary sequences of Csk (28), Chk (31), Src (32),
and Hck (33) in the peptide-binding lobe were aligned. This
alignment identified 29 residues that are uniquely conserved in
the Csk family (Fig. 1). Because Csk phosphorylation of kdSrc
is highly sensitive to ionic inhibition (data not shown), we first
focused on 14 polar and charged residues (Arg-279, Arg-281,
Arg-283, Glu-303, Arg-318, Asp-325, Ser-331, Lys-337, Asp-344,
Lys-362, Ser-381, Lys-393, Lys-401, and Glu-438). Among the 14,
Ser-331 is buried in the interior of Csk, and Arg-318, Lys-337,
and Asp-344 have been previously excluded as possible residues
to interact with Src (24, 34, 35), leaving 10 residues as potentially
part of the substrate-docking site. No obvious spatial pattern was
Fig. 1. Alignment of the amino acid sequences of Csk, Chk, Src, and Hck in the peptide-binding lobe. Residues that are uniquely conserved in the Csk family
are highlighted blue (polar or charged) or red (hydrophobic or Gly).
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observed when the uniquely conserved residues were mapped
onto the tertiary structure of Csk.
To determine which of these residues may be part of a
substrate-docking site, they were individually mutated to Ala
and the mutant enzymes were purified to apparent or near
homogeneity. For some reason, one of the mutants, Arg359Ala,
was not produced. By functional nature of the hypothetical
substrate-docking site, we reasoned that this site would be
critical for Csk activity toward its physiological substrate but not
important for phosphorylation of an artificial substrate. Thus, as
the initial screening, the kinase activities of the mutants toward
an artificial and a physiological substrate were determined (Fig.
2A). The artificial substrate used was polyE4Y, a random co-
polymer of Glu and Tyr in the ratio of 4:1. PolyE4Y lacks a
defined phosphorylation site or higher orders of structure and is
commonly used as a generic PTK substrate. The activity toward
polyE4Y, therefore, is considered as general kinase activity. The
physiological substrate used is a recombinantly expressed kinase-
defective Src (kdSrc) that contains a Lys295Met mutation. The
mutation inactivates Src but does not affect its ability to serve as
a specific substrate for Csk or Chk (10, 18). The use of kdSrc
instead of active Src eliminates interference to the assay by Src
autophosphorylation.
If a residue is part of the substrate-docking site of Csk, its
mutation to Ala will likely more dramatically decrease Csk
activity toward kdSrc than toward polyE4Y. Three of the 10
mutants, Arg279Ala, Arg281Ala, and Arg283Ala, displayed this
property, with the latter two exhibiting 80% of WT activity
toward polyE4Y but 20% of WT activity toward kdSrc.
Lys362Ala displayed the opposite effect, having a more dramatic
effect on polyE4Y phosphorylation than kdSrc phosphorylation.
This is representative of a group of Csk mutants that preferen-
tially affect phosphorylation of polyE4Y over kdSrc, which were
separately characterized (unpublished data). Mutation of the
other residues had similar effects on polyE4Y and kdSrc phos-
phorylation. Overall, Ala scanning mutagenesis implicated Arg-
281, Arg-283, and Arg-279 as part of the substrate-docking site.
Additional Residues Are Identified to Be Critical for Src Phosphory-
lation. Arg-279, Arg-281, and Arg-283 are located on -helix D,
a short helix located near the active site of Csk. In the tertiary
structure, these three residues form a triangle (Fig. 2B). Each
side of this triangle measures 15–16 Å. Two other residues,
Ser-280 and Phe-382, although not uniquely conserved in Csk
family, also fall within or near the area defined by the Arg
triangle and could be part of the substrate-docking site. They
were individually mutated to Ala, and the ability of the mutants
to phosphorylate kdSrc and polyE4Y was determined. Ser280Ala
and Phe382Ala displayed significantly less relative activity
toward kdSrc than toward polyE4Y (Fig. 2C), indicating that
these two residues are also part of the substrate-docking site.
Ser-284 and Ser-381 are located just outside of the Arg triangle
(Fig. 2B). The mutation of either one to Ala affected polyE4Y
and kdSrc phosphorylation equally (Fig. 2C), indicating that
these two residues were not specifically important for Src
recognition.
Two residues, Ser-273 and Asp-276, are located on the -helix
D, and between the Arg triangle and the active site (Fig. 2B). If
the Arg triangle and the active site of Csk form a continuous
binding surface for Src interaction, then these residues are also
likely to be important for Src phosphorylation by Csk. To test this
possibility, they were mutated to Ala and the mutants were
purified and analyzed (Fig. 2C). Ser273Ala displayed WT level
activity toward polyE4Y and 70% WT activity toward kdSrc.
Asp276Ala retained 40% of WT activity toward either
polyE4Y or kdSrc. This result suggests that Ser-273 is also part
of the substrate-docking site.
The above Ala scanning study identified six residues (Ser-273,
Arg-279, Ser-280, Arg-281, Arg-283, and Phe-382) as specifically
important for kdSrc phosphorylation. The first five are located
on -helix D, and the last one is located next to the helix in the
tertiary structure. Several residues immediately outside this
region were not specifically important for kdSrc phosphoryla-
Fig. 2. Ala scanning mutagenesis to identify the substrate-docking site on
Csk. (A) Ala scanning of polar or charged residues that are uniquely conserved
in the Csk family. The activity of the Ala mutants toward an artificial and a
physiological substrate are determined. (B) Structure of the Csk peptide-
binding lobe. Residues that are potentially part of the substrate-docking site,
the catalytic loop, and the activation loop are indicated. (C) Ala scanning of
residues in or near the identified substrate-docking site.








tion. Therefore, these six residues represent the major determi-
nants of the substrate-docking site.
Mutations of the Putative Substrate-Docking Site Convert Csk into a
Generically Active Kinase Unable to Phosphorylate, Regulate, or Bind
to Src. To further verify the substrate-docking site, two mutants,
one containing double mutations (DM) of Arg281Ala, and
Arg283Ala and the other containing quadruple mutations (QM)
of Ser280Ala, Arg281Ala, Arg283Ala, and Phe382Ala, were
generated. Ser-273 and Arg-279 were not included in these
mutants, because mutation of each had relatively minor effects
on kdSrc phosphorylation (Fig. 2). Fig. 3A compares the
Lineweaver-Burk plots of WT and mutant enzymes using kdSrc
as the variable substrate. Both mutants had dramatically de-
creased kcat and mildly higher Km values. Table 1 summarizes the
catalytic parameters of the two mutants using both kdSrc and
polyE4Y as the variable substrates. Toward kdSrc, the Km
increased 1.5-fold for DM and 3-fold for QM. Both mutants
had kcat values 15% of that of WT, resulting in a 20-fold or
more reduction in kcatKm ratio. In contrast, the mutants had
similar kcat and moderately increased Km toward polyE4Y,
resulting in a reduction of kcatKm ratio by 3-fold. This result
demonstrates that the mutated residues are specifically impor-
tant for kdSrc phosphorylation.
Because the Csk mutants were defective in phosphorylating
kdSrc, it was expected that they would be defective in regulating
Src by phosphorylation. This possibility was tested by a Src
inactivation assay (14) (Fig. 3B). Src expressed in and purified
from insect cells (36, 37) was incubated with WT or mutant Csk
(equal polyE4Y kinase activity were used for WT or mutant Csk)
in the presence of ATP and MgCl2 for 10 min, and then the Src
activity in the incubation was determined. If Csk or the mutants
were able to inactivate Src, the preincubation would result in a
decrease in Src activity. As expected, WT Csk inactivated Src,
but the two mutants did not. This result confirmed that the
mutations converted Csk into a generically active kinase without
the ability to recognize and phosphorylate Src.
If the mutated residues in DM and QM are indeed the
substrate-docking site, the mutants should have a much weaker
interaction with kdSrc than WT Csk. Pull-down assays were
performed, as described in Methods, to evaluate the interaction
of Csk to kdSrc (Fig. 4). GST-wtCsk, but not GST, was able to
pull down kdSrc (close to a 1:1 ratio), indicating that kdSrc was
binding specifically to Csk. Similarly, Csk mutants S273, K393,
and K401 were also able to pull down kdSrc, correlating to their
significant residual kdSrc kinase activity. In contrast, DM, QM,
R284, and F382 were not able to pull down kdSrc, in good
agreement with their inactivity to phosphorylate kdSrc. This
result further confirmed that the identified docking residues
were specifically responsible for binding to Src. Because these
residues are responsible for binding to Src and rendering Csk
effective in phosphorylating Src, we conclude that these residues
constitute the major determinants of the substrate-docking site.
Peptidic Mimic of the Substrate-Docking Site Specifically Inhibits the
Phosphorylation of kdSrc by Csk. As another independent test for
the identified substrate-docking site, the ability of peptides
mimicking the docking site as inhibitors for Csk was determined.
Peptides mimicking the substrate-docking site structure would
be expected to compete against Csk in binding to Src. Thus, they
should inhibit Csk phosphorylation of kdSrc but not that of
polyE4Y. To test this idea, three peptides were synthesized:
VDYLRS (P1), RSRGRS (P2), and RSVLGG (P3). They cover
residues V275 through Ser-280 (P1), Arg-279 through Ser-284
(P2), and Arg-283 through Gly-288 (P3). Note that P2 contained
four residues, Arg-279, Ser-280, Arg-281, and Arg-283, that are
key residues of the substrate-docking site of Csk. In contrast, P1
or P3 contained only at most two residues important for SFK
binding. P1 and P3 (up to 1 mM) did not inhibit Csk phosphor-
ylation of polyE4Y or kdSrc (data not shown). In contrast, P2
potently inhibited Csk phosphorylation of kdSrc (IC50 21	 3.8
M) but only moderately inhibited polyE4Y phosphorylation
(IC50  422 	 46 M) (Fig. 5). The differential inhibition of
Fig. 3. Effect of DM and QM on Csk kinase function. The details and rationale
of the mutations are described in the text. (A) Effect of docking site mutations
on Csk phosphorylation of kdSrc. (B) Effect of docking site mutations Csk’s
ability to inactivate Src.
Table 1. Catalytic parameters of Csk mutants
Activity with kdSrc Activity with polyE4Y
kcat, min1 Km, M
Relative
kcatKm kcat, min1 Km, gml
Relative
kcatKm
WT 53.8 	 17.2 5.7 	 2.2 1 89.6 	 5.6 95.4 	 16.6 1
DM 6.5 	 1.2 13.9 	 3.6 0.05 124.1 	 29.8 274.1 	 6.7 0.48
QM 7.6 	 4.2 22.9 	 9.4 0.03 111.1 	 27.8 322.2 	 32.7 0.37
Relative kcatKm  actual kcatKmactual kcatKm of WT.
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kdSrc and polyE4Y phosphorylation indicated that P2 specifi-
cally interfered with the interaction between Csk and kdSrc. This
result further indicates that the residue cluster located on -helix
D and mimicked by P2 contained key determinants of the
substrate-docking site.
Discussion
PTKs of the Csk family specifically phosphorylate SFKs on a
C-terminal tail Tyr residue and regulate their activity. This
system is chosen to investigate PTK substrate specificity because
the exclusive PTK–substrate relationship is well established in
vivo and in vitro, and extensive structural and biological data are
available on Csk and SFKs to assist such studies. One unique
feature of this system that was central to our strategy was that
Csk and Chk shared functional identity but relatively low se-
quence identity (54%). This feature allowed us to locate some
key residues in the docking site by evaluating uniquely conserved
residues in Csk family.
The identified substrate-docking site of Csk is composed of six
residues, Ser-273, Arg-279, Ser-280, Arg-281, Arg-283, and Phe-
382. This identification of the substrate-docking site is supported
Fig. 6. Structures of Csk catalytic domain and the substrate-docking site. (A)
Ribbon structure of Csk with identified residues in the substrate-docking site
shown in a ball-and-stick model. Several loop structures relevant to peptide
substrate binding and catalysis are indicated by arrows. (B) Surface structure
of Csk (yellow) and the substrate-docking site (colored by electrostatic poten-
tial). The active site cleft is indicated.
Fig. 4. Pull-down assay to determine the interaction of Csk and mutants with
kdSrc. (A) Purified GST, GST-Csk, GST-DM, and GST-QM. (B and C) kdSrc
pull-down assay with various Csk variants. Each of the purified GST or fusion
proteins (100 pmol) was incubated with purified kdSrc (200 pmol) and pre-
cipitated with glutathione-agarose. The proteins retained by the beads were
analyzed by SDSPAGE and Coomassie blue staining.
Fig. 5. Inhibition of Csk activity by peptide P2 that mimics the substrate-
docking site. The Ki of P2 inhibition of Csk is 21 M toward kdSrc but 422 M
toward polyE4Y.








by several lines of evidence. First, several of the key residues of
the docking site are uniquely conserved in Csk and Chk. The
unique conservation is consistent with Csk and Chk being the
only two kinases able to phosphorylate SFKs on Ytail. Second,
mutations of the residues within the docking site abolished Csk
activity toward Src without significantly affecting its general
kinase activity. Mutation of many residues outside this region did
not preferentially affect Csk’s ability to phosphorylate the
physiological substrate. Third, Csk mutants containing multiple
point mutations in the docking site resulted in a 95% loss of
Csk activity toward kdSrc but only a modest decrease in activity
toward artificial substrate, effectively converting Csk into a
generic PTK unable to phosphorylate Src. Correspondingly, the
Csk mutants were unable to regulate Src activity. Fourth, the loss
of activity toward kdSrc correlates to the loss of ability to
physically bind to kdSrc, indicating that the mutated site is
indeed critical for Csk–Src interaction. Fifth, a peptide mimick-
ing part of the docking site potently inhibited Csk phosphory-
lation of kdSrc but only moderately inhibited Csk activity toward
an artificial substrate. These results demonstrate that the sub-
structure consisting of the -helix D and Phe-382 is indeed the
docking site that specifically interacts with SFKs for efficient
phosphorylation.
At present, it is difficult to assign quantitative contributions to
the individual residues. The identified residues (Fig. 2B), con-
taining three positively charged residues, two polar residues, and
one hydrophobic residue, appear well suited to provide a com-
plex surface for highly specific and unique interaction with the
substrate. The docking site is located near the active site (Fig. 6)
and appears well positioned for Src docking. Crystallized IRK–
peptide substrate complexes (38) and mutagenic studies of other
PTKs (39) indicate that the P  1 loop provides the main
platform for peptide substrate binding to PTKs. It is likely that
the P  1 loop in Csk performs the same function in binding to
SFK C-terminal tail and presents Ytail to the active site. The
docking site is located on the same side of the kinase molecule
as the P 1 loop. It can be envisioned that substrate-docking site
would interact with the docking determinants on SFKs, which
would bring the C-terminal tail peptide to Csk active site.
Because Src binding and phosphorylation are both abolished by
docking site mutations, it appears that the docking interaction
may be primarily responsible for SFKs recognition by Csk.
This work raises several important questions that remain to be
answered. First, what are the specificity determinants on SFKs
that allow them to be specifically recognized by Csk and Chk?
We reason that such determinants would be a surface area
complementary to the Csk substrate-docking site. The identifi-
cation of the docking site on Csk will facilitate the identification
of such determinants on SFKs. Second, it is unclear whether
other PTKs will use a similar mechanism for recognizing their
physiological substrates. Csk family PTKs have unusually strict
substrate specificity in that they only phosphorylate SFKs. Other
PTKs may phosphorylate multiple families of protein substrates.
Alignments of primary and tertiary structures of PTKs indicate
that the structures of -helix D are highly variable between PTK
families, consistent with the possibility of its being a key structure
for substrate specificity determination. Third, it is interesting
that mutations of the docking site only moderately affected the
Km of Csk for kdSrc but more dramatically affected the kcat. We
started this work with the expectation that the docking site would
mainly affect the complementarity between the enzyme and the
substrate, and thus perturbation to the docking site would more
significantly affect the Km. The large decrease in kcat caused by
the mutations suggest that the docking interaction is critical for
Csk transition state complementarity with SFKs instead.
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